
|Videos|December 23, 2020
R/R Multiple Myeloma: Review of the CARTITUDE Trial
Author(s)Targeted Oncology
Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
2
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5


































